Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Recent Developments in RNA Therapeutics for Humans Disorders

Document Type : Review Article

Authors

Farnaz Roshan Mehr 1
Fatemeh Gabeleh 2
Roshanak Jazayeri 3

1 Department of Medical Biotechnology, Golestan University of Medical Sciences, Gorgan, Iran

2 Department of Medical Virology, Tarbiat Modares University, Tehran, Iran

3 Non-communiable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

https://doi.org/10.22034/pmj.2024.715088
Abstract
Recent research has uncovered a wide range of RNAs, including noncoding RNAs, and have discovered their varied modes of action inside cells. These ribonucleic acids (RNAs) play a crucial role in controlling many cellular processes and are thus anticipated to be significant targets for the treatment of human disorders. In recent years, RNA-based medicinal approaches have made significant advancements alongside their comprehensive functional research. Following extensive study and experimentation, medications based on antisense RNAs and small interfering RNAs have been successfully created and are already being used in clinical settings. Furthermore, there is now ongoing research focused on the development of pharmaceuticals using RNA aptamers and messenger RNA. In addition to the advancement of RNA-based medications, many techniques have been devised to effectively deliver RNA drugs into cells. RNA treatment offers several benefits compared to current therapeutics based on small molecules or monoclonal antibodies, mostly due to its ability to selectively target all genes inside cells. The purpose of this article is to provide an overview of the introduction of various RNA-based technologies and the introduction of RNA-based drugs in the market. In addition, the future prospects of RNA therapy will be addressed.

Keywords

Antisense
RNA
Aptamer
RNA interference
  1. Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell death & disease. 2022;13(7):644.
  2. Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020;19(7):441-2.
  3. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell metabolism. 2018;27(4):714-39.
  4. Zogg H, Singh R, Ro S. Current advances in RNA therapeutics for human diseases. International journal of molecular sciences. 2022;23(5):2736.
  5. Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Frontiers in genetics. 2019;10:478.
  6. Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annual review of medicine. 2019;70(1):307-21.
  7. Agrawal S. Remembering Paul C. Zamecnik, MD," father of antisense"(1912-2009). Oligonucleotides. 2010;20(1):47-50.
  8. Crooke ST, Baker BF, Crooke RM, Liang X-h. Antisense technology: an overview and prospectus. Nature reviews Drug discovery. 2021;20(6):427-53.
  9. Liang X-H, Sun H, Nichols JG, Crooke ST. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Molecular therapy. 2017;25(9):2075-92.
  10. Desterro J, Bak-Gordon P, Carmo-Fonseca M. Targeting mRNA processing as an anticancer strategy. Nature Reviews Drug Discovery. 2020;19(2):112-29.
  11. Li D, Mastaglia FL, Fletcher S, Wilton SD. Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends in Pharmacological Sciences. 2018;39(11):982-94.
  12. Nakamura A, Takeda Si. Exon-skipping therapy for Duchenne muscular dystrophy. The Lancet. 2011;378(9791):546-7.
  13. Aartsma-Rus A. FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic acid therapeutics. 2017;27(2):67-9.
  14. Burr P, Reddivari AKR. Spinal muscle atrophy. 2020.
  15. Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Molecular Therapy. 2017;25(5):1125-31.
  16. Mendell JR, Rodino‐Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of neurology. 2013;74(5):637-47.
  17. Sekijima Y. Hereditary transthyretin amyloidosis. 2021.
  18. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018;379(1):22-31.
  19. Kim DH, Rossi JJ. RNAi mechanisms and applications. Biotechniques. 2008;44(5):613-6.
  20. Agrawal N, Dasaradhi P, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiology and molecular biology reviews. 2003;67(4):657-85.
  21. Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc journal: a journal of postdoctoral research and postdoctoral affairs. 2016;4(7):35.
  22. Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Disease models & mechanisms. 2021;14(4):dmm047662.
  23. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2010;1803(11):1231-43.
  24. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Frontiers in endocrinology. 2018;9:402.
  25. Li L-C, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. Small dsRNAs induce transcriptional activation in human cells. Proceedings of the National Academy of Sciences. 2006;103(46):17337-42.
  26. Tan CP, Sinigaglia L, Gomez V, Nicholls J, Habib NA. RNA activation—a novel approach to therapeutically upregulate gene transcription. Molecules. 2021;26(21):6530.
  27. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nature chemical biology. 2007;3(3):166-73.
  28. Hoy SM. Patisiran: first global approval. Drugs. 2018;78:1625-31.
  29. Kaku M, Berk JL, editors. Neuropathy associated with systemic amyloidosis. Seminars in Neurology; 2019: Thieme Medical Publishers.
  30. Scott LJ, Keam SJ. Lumasiran: first approval. Drugs. 2021;81:277-82.
  31. Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. Journal of the American Society of Nephrology. 2017;28(2):494-503.
  32. Lamb YN. Inclisiran: first approval. Drugs. 2021;81:389-95.
  33. Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Molecular cancer. 2021;20(1):33.
  34. Pollard C, De Koker S, Saelens X, Vanham G, Grooten J. Challenges and advances towards the rational design of mRNA vaccines. Trends in molecular medicine. 2013;19(12):705-13.
  35. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949):1465-8.
  36. Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science. 1992;255(5047):996-8.
  37. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Current opinion in immunology. 2020;65:14-20.
  38. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet. 2017;390(10101):1511-20.
  39. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome medicine. 2017;9:1-16.
  40. Egan KP, Hook LM, Naughton A, Pardi N, Awasthi S, Cohen GH, et al. An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathogens. 2020;16(7):e1008795.
  41. Wang F, Xiao W, Elbahnasawy MA, Bao X, Zheng Q, Gong L, et al. Optimization of the linker length of mannose-cholesterol conjugates for enhanced mRNA delivery to dendritic cells by liposomes. Frontiers in Pharmacology. 2018;9:980.
  42. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine. 2020;383(16):1544-55.
  43. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020;383(27):2603-15.
  44. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine. 2021;384(5):403-16.
Personalized and Precision Medicine Journal
Volume 9, Issue 34
Original article
Summer 2024
Pages 1-8

  • Receive Date 02 May 2024
  • Revise Date 15 July 2024
  • Accept Date 26 August 2024

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us